Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment. Issue 2 (2nd February 2017)

• Record Type: Journal Article
• Authors: CHUA, Michael E.; SEE, Manuel C.; ESMEŇA, Ednalyn B.; BALINGIT, Jaime C.; MORALES, Marcelino L.
• Is Part Of: LUTS. Volume 10:Issue 2(2018)
• Page Start: 135
• Page End: 142
• Publication Date: 2017-02-02
• Subjects: gabapentin -- overactive bladder -- randomized controlled trial -- solifenacin; Urology -- Periodicals; Urologic Diseases -- Periodicals; Urinary Tract Physiological Phenomena -- Periodicals; 616.62
• DOI: 10.1111/luts.12152
• Languages: English
• ISSNs: 1757-5664

Abstract

Abstract : Objective: To evaluate the efficacy and safety of gabapentin in comparison to solifenacin succinate and placebo for the treatment of adult patients with overactive bladder (OAB). Method: A 12‐week, randomized, double‐blind, double dummy placebo‐controlled, clinical trial was conducted between October 2010 and August 2014 at a tertiary medical center. Eligible and consenting patients included were randomized into three treatment groups (placebo, gabapentin and solifenacin). After a 12‐week treatment period, an intention to treat analysis was applied to assess between group differences on the micturitions and urgency episodes per 24 h; which were evaluated by 3‐day micturition diary mean change from baseline to post treatment. Health related quality of life (HRQOL) domains were likewise assessed by OAB questionnaire (OAB‐q). Adverse event were monitored and summarized. Study results were analyzed at statistical significance of 0.05. (ClinicalTrials.gov ID NCT01486706) Result: A total of 94 participants were included for end‐study efficacy and safety analysis. Compared to placebo, gabapentin and solifenacin have statistically significant improvement in mean number of micturitions per 24 h (adjusted mean difference [AMD] −1.179, 95%CI −1.98, −0.38; P < 0.001; −1.706, 95%CI −2.52, −0.09; P < 0.001; respectively), and in mean number of urgency episodes per 24 h (AMD −0.903, 95%CI −1.44, −0.37; P < 0.001; −0.896, 95%CI −1.44, −0.35; P < 0.001). Gabapentin also demonstrated significant improvement over the solifenacin in the mean number of nocturia episodes/24 h (AMD −0.607, 95%CI −1.04, −0.18; P < 0.001). Adverse event related to gabapentin treatment was lesser than solifenacin, and comparable to placebo. Conclusion: Gabapentin treatment with acceptable safety profile, improves OAB symptoms and HRQOL domains.